ArticleMaternal and child health journal2023
Prenatal Substance Exposure and Neonatal Abstinence Syndrome: State Estimates from the 2016-2020 Transformed Medicaid Statistical Information System.
Article in Maternal and child health journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Neonatal Outcomes Associated with Maternal-Factor-Related Diagnoses: Real-World Evidence from a National Inpatient Database (2010-2025).Medical sciences (Basel, Switzerland) · 2026Article
- Expanding evidence-based care for opioid-exposed mother-infant dyads: a mixed-methods study.Maternal health, neonatology and perinatology · 2026Article
- Adolescent prefrontal and amygdala molecular signatures of perinatal morphine versus buprenorphine exposure in mice.Neurotoxicology · 2026Article
- Limbic System Microstructure in Neonates With Antenatal Opioid Exposure.JAMA network open · 2026Article
- Longitudinal academic achievement in children with a history of neonatal abstinence syndrome: a retrospective observational cohort study.Lancet regional health. Americas · 2026Article
- Fetal brain volumes and brain gyrification index associated with opioid exposure.Brain communications · 2026Article
- Maternal Opioid-related Diagnosis in Pregnancy and Risk of Adverse Perinatal Outcomes.Journal of addiction medicine · 2025Article
- Placental MRI texture features in prenatal exposure to opioids and tobacco.Scientific reports · 2025Article
- Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes.JAMA pediatrics · 2025Article
- A Pooled Sample Study of Opioid Use Disorder Treatment Wait Time Among a Pregnant Population in New York.Epidemiologia (Basel, Switzerland) · 2025Article
- Systemic barriers and stigma: Healthcare provider perspectives on perinatal and neonatal care in the fentanyl crisis.Journal of substance use and addiction treatment · 2025Article
- Beyond a simple cause and effect relationship: Exploring the long-term outcomes of children prenatally exposed to opioids and other substances.Seminars in perinatology · 2025Review
- The limitations of using Medicaid administrative data in abortion research.Contraception · 2025Article
- Early Intervention Enrollment Among Substance-exposed Infants in Massachusetts: A Population-level Analysis.Journal of developmental and behavioral pediatrics : JDBPArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEstimating Neonatal Abstinence Syndrome (NAS) and prenatal substance exposure rates in Medicaid can help target program efforts to improve access to services.
methodsThe data for this study was extracted from the 2016-2020 Transformed Medicaid Statistical Information System (T-MSIS) Analytic Files (TAF) Research Identifiable Files (RIF) and included infants born between January 1, 2016 and December 31, 2020 with a either a NAS diagnosis or prenatal substance exposure.
resultsBetween 2016 and 2020, the estimated national rate of NAS experienced a 18% decline, while the estimated national rate of prenatal substance exposure experienced a 3.6% increase. At the state level in 2020, the NAS rate ranged from 3.2 per 1000 births (Hawaii) to 68.0 per 1000 births (West Virginia). Between 2016 and 2020, 28 states experienced a decline in NAS births and 20 states had an increase in NAS rates. In 2020, the lowest prenatal substance exposure rate was observed in New Jersey (9.9 per 1000 births) and the highest in West Virginia (88.1 per 1000 births). Between 2016 and 2020, 38 states experienced an increase in the rate of prenatal substance exposure and 10 states experienced a decline. DISCUSSION: Estimated rate of NAS has declined nationally, but rate of prenatal substance exposure has increased, with considerable state-level variation. The reported increase in prenatal substance exposure in the majority of US states (38) suggest that substances other than opioids are influencing this trend. Medicaid-led initiatives can be used to identify women with substance use and connect them to services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.